NC
RGNX icon

Napatree Capital’s Regenxbio RGNX Stock Holding History

Napatree Capital’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$226K Sell
31,675
-1,850
-6% -$13.8K 0.13% 185
2024
Q4 		$259K Sell
33,525
-1,600
-5% -$15K 0.15% 155
2024
Q3 		$368K Sell
35,125
-14,639
-29% -$178K 0.26% 108
2024
Q2 		$582K Buy
49,764
+4,176
+9% +$65K 0.47% 73
2024
Q1 		$700K Buy
45,588
+5,470
+14% +$97.3K 0.68% 57
2023
Q4 		$720K Buy
+40,118
New +$707K 0.72% 53

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Napatree Capital's RGNX Position: Q1 2025 in Review

Napatree Capital reduced its Regenxbio (RGNX) stake by 5.5% in Q1 2025, selling an estimated $13.8K and leaving 31,675 shares worth $226K. The position accounts for 0.13% of the portfolio, ranked #185.

Napatree Capital first reported a position in RGNX in Q4 2023 and has held it in 6 quarters since. The position peaked at $720K in Q4 2023. 164 funds tracked by Wall St. Rank hold RGNX as of Q1 2025.

  • Napatree Capital held 31,675 shares of Regenxbio worth $226K as of Q1 2025.
  • Napatree Capital sold 1,850 Regenxbio shares in Q1 2025, an estimated $13.8K.
  • Regenxbio made up 0.13% of Napatree Capital's portfolio in Q1 2025, its #185 holding.
  • Napatree Capital first reported a position in Regenxbio in Q4 2023 and has held it in 6 quarters since.
  • Napatree Capital's Regenxbio position peaked at $720K in Q4 2023.
  • 164 funds tracked by Wall St. Rank held Regenxbio as of Q1 2025.

Based on Napatree Capital's 13F filing for Q1 2025, filed 2 May 2025.